Ethacrynic acid (tablet)

Revision as of 01:31, 2 July 2014 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search

Ethacrynic acid (tablet)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Ethacrynic acid (tablet) is a loop diuretic that is FDA approved for the {{{indicationType}}} of edema associated with congestive heart failure, cirrhosis, and renal disease. It is also indicated for short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. Common adverse reactions include electrolyte imbalance, anorexia, malaise, abdominal discomfort, dysphagia, nausea, vomiting, diarrhea, agranulocytosis, neutropenia, deafness, tinnitus, and vertigo.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.
Edema
  • Dosage must be regulated carefully to prevent a more rapid or substantial loss of fluid or electrolyte than is indicated or necessary.
  • The magnitude of diuresis and natriuresis is largely dependent on the degree of fluid accumulation present in the patient. Similarly, the extent of potassium excretion is determined in large measure by the presence and magnitude of aldosteronism.
  • Dosing Information
Initial Dose
  • The smallest dose required to produce gradual weight loss (about 1 to 2 pounds per day) is recommended.
  • Onset of diuresis usually occurs at 50 to 100 mg PO qd for adults. After diuresis has been achieved, the minimally effective dose (usually from 50 to 200 mg PO qd) may be given on a continuous or intermittent dosage schedule.
  • Dosage adjustments are usually in 25 to 50 mg increments to avoid derangement of water and electrolyte excretion.
  • The patient should be weighed under standard conditions before and during the institution of diuretic therapy with this compound. Small alterations in dose should effectively prevent a massive diuretic response.
  • The following schedule may be helpful in determining the smallest effective dose.
  • Day 1 — 50 mg once daily after a meal
  • Day 2 — 50 mg twice daily after meals, if necessary
  • Day 3 — 100 mg in the morning and 50 to 100 mg following the afternoon or evening meal, depending upon response to the morning dose.
  • A few patients may require initial and maintenance doses as high as 200 mg PO bid. These higher doses, which should be achieved gradually, are most often required in patients with severe, refractory edema.
Maintenance Dose
  • Ethacrynic acid may be given intermittently after an effective diuresis is obtained with the regimen outlined above.
  • Dosage may be on an alternate daily schedule or more prolonged periods of diuretic therapy may be interspersed with rest periods. Such an intermittent dosage schedule allows time for correction of any electrolyte imbalance and may provide a more efficient diuretic response.
  • The chloruretic effect of this agent may give rise to retention of bicarbonate and a metabolic alkalosis. This may be corrected by giving chloride (ammonium chloride or arginine chloride). Ammonium chloride should not be given to cirrhotic patients.
  • Ethacrynic acid has additive effects when used with other diuretics. For example, a patient who is on maintenance dosage of an oral diuretic may require additional intermittent diuretic therapy, such as an organomercurial, for the maintenance of basal weight. The intermittent use of ethacrynic aicd orally may eliminate the need for injections of organomercurials. Small doses of ethacrynic acid may be added to existing diuretic regimens to maintain basal weight.
  • This drug may potentiate the action of carbonic anhydrase inhibitors, with augmentation of natriuresis and kaliuresis. Therefore, when adding ethacrynic acid the initial dose and changes of dose should be in 25 mg increments, to avoid electrolyte depletion.
  • While many patients do not require supplemental potassium, the use of potassium chloride or potassium-sparing agents, or both, during treatment with ethacrynic acid is advisable, especially in cirrhotic or nephrotic patients and in patients receiving digitalis.
  • Salt liberalization usually prevents the development of hyponatremia and hypochloremia. During treatment with ethacrynic acid, salt may be liberalized to a greater extent than with other diuretics. Cirrhotic patients, however, usually require at least moderate salt restriction concomitant with diuretic therapy.
Intravenous Use
  • Intravenous ethacrynic acid is for intravenous use when oral intake is impractical or in urgent conditions, such as acute pulmonary edema.
  • The usual intravenous dose for the average sized adult is 50 mg, or 0.5–1.0 mg/kg of body weight.
  • Usually only one dose has been necessary; occasionally a second dose at a new injection site, to avoid possible thrombophlebitis, may be required. A single intravenous dose not exceeding 100 mg has been used in critical situations.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ethacrynic acid (tablet) in adult patients.

Non–Guideline-Supported Use

Hypertension
  • Dosing Information

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Edema
  • Dosing Information
Initial Dose
  • The initial dose should be 25 mg PO qd. Careful stepwise increments in dosage of 25 mg should be made to achieve effective maintenance.
Maintenance Dose
  • Ethacrynic acid may be given intermittently after an effective diuresis is obtained with the regimen outlined above.
  • Dosage may be on an alternate daily schedule or more prolonged periods of diuretic therapy may be interspersed with rest periods. Such an intermittent dosage schedule allows time for correction of any electrolyte imbalance and may provide a more efficient diuretic response.
Intravenous Use
  • Insufficient pediatric experience precludes recommendation for this age group.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Ethacrynic acid (tablet) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Ethacrynic acid (tablet) in pediatric patients.

Contraindications

Warnings

  • The effects of ethacrynic acid on electrolytes are related to its renal pharmacologic activity and are dose dependent. The possibility of profound electrolyte and water loss may be avoided by weighing the patient throughout the treatment period, by careful adjustment of dosage, by initiating treatment with small doses, and by using the drug on an intermittent schedule when possible. When excessive diuresis occurs, the drug should be withdrawn until homeostasis is restored. When excessive electrolyte loss occurs, the dosage should be reduced or the drug temporarily withdrawn.
  • Initiation of diuretic therapy with ethacrynic acid in the cirrhotic patient with ascites is best carried out in the hospital. When maintenance therapy has been established, the individual can be satisfactorily followed as an outpatient. Ethacrynic acid should be given with caution to patients with advanced cirrhosis of the liver, particularly those with a history of previous episodes of electrolyte imbalance or hepatic encephalopathy. Like other diuretics it may precipitate hepatic coma and death.
  • Too vigorous a diuresis, as evidenced by rapid and excessive weight loss, may induce an acute hypotensive episode. In elderly cardiac patients, rapid contraction of plasma volume and the resultant hemoconcentration should be avoided to prevent the development of thromboembolic episodes, such as cerebral vascular thromboses and pulmonary emboli which may be fatal. Excessive loss of potassium in patients receiving digitalis glycosides may precipitate digitalis toxicity. Care should also be exercised in patients receiving potassium-depleting steroids.
  • A number of possibly drug-related deaths have occurred in critically ill patients refractory to other diuretics. These generally have fallen into two categories: (1) patients with severe myocardial disease who have been receiving digitalis and presumably developed acute hypokalemia with fatal arrhythmia; (2) patients with severely decompensated hepatic cirrhosis with ascites, with or without accompanying encephalopathy, who were in electrolyte imbalance and died because of intensification of the electrolyte defect.
  • Deafness, tinnitus, and vertigo with a sense of fullness in the ears have occurred, most frequently in patients with severe impairment of renal function. These symptoms have been associated most often with intravenous administration and with doses in excess of those recommended. The deafness has usually been reversible and of short duration (one to 24 hours). However, in some patients the hearing loss has been permanent. A number of these patients were also receiving drugs known to be ototoxic. Ethacrynic acid may increase the ototoxic potential of other drugs.
  • Lithium generally should not be given with diuretics
Precautions
General
  • The safety and efficacy of ethacrynic acid in hypertension have not been established. However, the dosage of coadministered antihypertensive agents may require adjustment.
  • Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. A transient increase in serum urea nitrogen may occur. Usually, this is readily reversible when the drug is discontinued.
  • A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein; a reduction in the usual anticoagulant dosage may be required in patients receiving both drugs.
  • Ethacrynic acid may increase the risk of gastric hemorrhage associated with corticosteroid treatment.
Laboratory Tests
  • Frequent serum electrolyte, CO2 and BUN determinations should be performed early in therapy and periodically thereafter during active diuresis. Any electrolyte abnormalities should be corrected or the drug temporarily withdrawn.
  • Increases in blood glucose and alterations in glucose tolerance tests have been observed in patients receiving Ethacrynic acid.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Ethacrynic acid (tablet) in the drug label.

Postmarketing Experience

Central Nervous System

Headache, fatigue, apprehension, confusion.

Special Senses

Deafness, tinnitus and vertigo with a sense of fullness in the ears, and blurred vision have occurred.

Hematologic

Agranulocytosis or severe neutropenia has been reported in a few critically ill patients also receiving agents known to produce this effect. Thrombocytopenia has been reported rarely. Henoch-Schönlein purpura has been reported rarely in patients with rheumatic heart disease receiving multiple drug therapy.

Gastrointestinal

Anorexia, malaise, abdominal discomfort or pain, dysphagia, nausea, vomiting, and diarrhea have occurred. These are more frequent with large doses or after one to three months of continuous therapy. A few patients have had sudden onset of profuse, watery diarrhea. Gastrointestinal bleeding has occurred in some patients. Rarely, acute pancreatitis has been reported.

Metabolic

Reversible hyperuricemia and acute gout have been reported. Acute symptomatic hypoglycemia with convulsions occurred in two uremic patients who received doses above those recommended. Hyperglycemia has been reported. Rarely, jaundice and abnormal liver function tests have been reported in seriously ill patients receiving multiple drug therapy

Miscellaneous

Skin rash, fever, chills, hematuria.

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Ethacrynic acid (tablet) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Ethacrynic acid (tablet) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Ethacrynic acid (tablet) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Ethacrynic acid (tablet) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Ethacrynic acid (tablet) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Ethacrynic acid (tablet) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Ethacrynic acid (tablet) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous
  • To reconstitute the dry material, add 50 mL of 5 percent Dextrose Injection, or Sodium Chloride Injection to the vial. Occasionally, some 5 percent Dextrose Injection solutions may have a low pH (below 5). The resulting solution with such a diluent may be hazy or opalescent. Intravenous use of such a solution is not recommended. Inspect the vial containing intravenous ethacrynic acid for particulate matter and discoloration before use.
  • The solution may be given slowly through the tubing of a running infusion or by direct intravenous injection over a period of several minutes. Do not mix this solution with whole blood or its derivatives. Discard unused reconstituted solution after 24 hours.
  • Ethacrynic acid should not be given subcutaneously or intramuscularly because of local pain and irritation.

Monitoring

There is limited information regarding Monitoring of Ethacrynic acid (tablet) in the drug label.

Condition1

Description

IV Compatibility

There is limited information regarding IV Compatibility of Ethacrynic acid (tablet) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Ethacrynic acid (tablet) in the drug label.

Pharmacology

There is limited information regarding Ethacrynic acid (tablet) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Ethacrynic acid (tablet) Mechanism of Action in the drug label.

Structure

There is limited information regarding Structure of Ethacrynic acid (tablet) in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Ethacrynic acid (tablet) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Ethacrynic acid (tablet) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Ethacrynic acid (tablet) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Ethacrynic acid (tablet) in the drug label.

Condition1

Description

How Supplied

There is limited information regarding Ethacrynic acid (tablet) How Supplied in the drug label.

Storage

There is limited information regarding Ethacrynic acid (tablet) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Ethacrynic acid (tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Ethacrynic acid (tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Ethacrynic acid (tablet) in the drug label.

Precautions with Alcohol

Alcohol-Ethacrynic acid (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.[5]

Brand Names

Edecrin®

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Russell, R. P. (1968). "Metabolic and hypotensive effects of ethacrynic acid. Comparative study with hydrochlorothiazide". JAMA: The Journal of the American Medical Association. 205 (1): 81–85. doi:10.1001/jama.205.1.81. ISSN 0098-7484.
  2. ↑ Davidov, M.; Kakaviatos, N.; Finnerty, F. A. (1967). "Antihypertensive Properties of Furosemide". Circulation. 36 (1): 125–135. doi:10.1161/01.CIR.36.1.125. ISSN 0009-7322.
  3. ↑ Conway, J.; Leonetti, G. (1965). "Hypotensive Effect of Ethacrynic Acid". Circulation. 31 (5): 661–664. doi:10.1161/01.CIR.31.5.661. ISSN 0009-7322.
  4. ↑ Brest, Albert N.; Onesti, Gaddo; Seller, Robert; Ramirez, Osvaldo; Heider, Charles; Moyer, John H. (1965). "Pharmacodynamic effects of a new diuretic drug, ethacrynic acid∗". The American Journal of Cardiology. 16 (1): 99–105. doi:10.1016/0002-9149(65)90013-5. ISSN 0002-9149.
  5. ↑ "EDECRIN (ethacrynic acid) tablet".
  6. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Ethacrynic acid (tablet)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Ethacrynic acid (tablet)
 |Label Name=No image.jpg

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Ethacrynic_acid_(tablet)&oldid=985153"